Eisai stock

4523 · TSE · JPY

Compare Eisai
¥5,280.00Change from previous close: +1.81%Absolute change: +¥94.00

Close · November 16, 2026

Price history

+12.94% over the period

1 year: from ¥4,675.00 (November 17, 2025) to ¥5,280.00 (November 16, 2026), +12.94%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026¥5,280.00
October 30, 2026¥5,052.00
September 30, 2026¥4,855.00
August 31, 2026¥4,740.00
July 31, 2026¥4,828.00
June 30, 2026¥4,119.00
May 29, 2026¥3,984.00
April 30, 2026¥4,687.00
March 31, 2026¥4,871.00
February 27, 2026¥5,241.00
January 30, 2026¥4,311.00
December 30, 2025¥4,660.00
November 28, 2025¥4,897.00
November 17, 2025¥4,675.00

At a glance

  • The company

    Research, develop, manufacture and sell pharmaceuticals including oncology, neurology and other therapeutic treatments

  • Latest results

    Quarter to September 30, 2026 · EPS ¥41.47 (estimate ¥56.31)

TickerLandia's take on Eisai

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low¥3,660.00
52-wk high¥5,284.00

−0.08% from the 52-week high

Analysts · 14 analysts

Average target¥4,625.00−12.41% vs. price

Buy 4 · Hold 9 · Sell 1 · Buy

TickerLandia Fingerprint: Eisai

Compared with similar companies: very high dividend and very high earnings stability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Eisai is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2026), Eisai's P/E today is 38.6, in line with the median of its last 10 fiscal years (36.5; between 18.7 and 50.5 from 2017 to 2026). Eisai's P/E (trailing 12 months): 33.3, +17% against the median of a group of 11 similar companies (28.4).

P/E compared with its history

Compared with 11 similar companies

Eisai's metrics compared with similar companies
MetricEisaiPosition in the groupBand
P/E (trailing 12 months)33.3Middle
Forward P/E25.6Middle
Operating margin6.7%Low
ROE5.1%Low
Debt/equity0.28Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Eisai. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥235.63B

Latest quarter · Q3 2026

Net income

¥11.69B

Latest quarter · Q3 2026

Quarterly net margin

5.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
¥1.46T
P/E
33.3
EPS
¥155.59
Volume
1.57M
Daily trading
€40.54M
Dividend yield
3.03%
Last ex-dividend on September 29, 2026

How Eisai is changing

All results
  • Revenue grew 5.0% a year on average over the last 5 years

  • Free cash flow equal to 83% of net income

Returns

Eisai returns with dividends

¥1,000 invested in Eisai 5 years ago, on November 16, 2021, would be worth ¥734 today with dividends reinvested: −26.60% in total, −6.00% per year. On price alone it would be ¥639 (−36.10%).

PeriodEisaiNikkei 225¥1,000 becomes
1 month+7.32%−6.39%¥1,073
6 months+11.79%−0.42%¥1,118
Year to date+13.30%+21.48%¥1,133
1 year+16.70%+21.52%¥1,167
3 years−24.91%+82.95%¥751
5 years−26.60%+105.15%¥734
10 years−2.78%+242.35%¥972

Over the last 6 months it has done better than 44% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment

The chart in detail

Eisai: technical analysis

Eisai is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 58.5% below its all-time closing high (¥12,710.00, June 22, 2021).

Trend
Upward
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+13.39%

Active signals

  • New 52-week high.

Support and resistance

Price areas where Eisai has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price¥5,280.00
  3. Support¥5,253.33−0.51%3 touches, last on November 5, 2026
  4. Support¥5,157.33−2.32%3 touches, last on October 23, 2026
  5. Support¥5,021.50−4.90%2 touches, last on September 25, 2026

Volatility and risk

Over the last year it has moved little with the Nikkei 225.

Beta (1 year) vs Nikkei 225
0.13
Volatility (60 sessions, annualised)
30.4%
Largest fall in the last year
−28.96%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Eisai: seasonality

Average monthly price change over 37 years

−1.9%Jan+1.2%Feb−1.1%Mar+0.5%Apr+1.0%May+2.7%Jun+0.0%Jul+1.6%Aug+1.6%Sep+0.5%Oct+0.1%Nov+1.0%Dec

Over the last 37 years, the strongest month for Eisai has been June: +2.71% on average, positive in 20 years out of 37. The weakest has been January: −1.86% on average, positive in 10 years out of 36. November, the current month, has been positive in 20 years out of 36 (+0.05% on average).

Show chart data
MonthAverageMedianPositive years
January−1.86%−1.40%10 of 36
February+1.18%−0.52%18 of 37
March−1.12%−2.17%13 of 37
April+0.53%0.00%17 of 37
May+1.01%+0.73%22 of 37
June+2.71%+1.18%20 of 37
July+0.02%−0.24%17 of 37
August+1.56%+2.78%23 of 37
September+1.62%+1.12%19 of 37
October+0.46%−1.47%14 of 37
November+0.05%+0.92%20 of 36
December+1.01%+1.45%24 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Eisai and its competitors

Eisai is known mainly through Lenvima, LEQEMBI and Dayvigo, the products of a Japanese pharmaceutical company that researches, develops, manufactures and sells drugs in Japan and abroad. Its focus lies in neurology and oncology, and its range includes prescription drugs and over-the-counter medicines. LEQEMBI is a humanized IgG1 monoclonal antibody against amyloid-beta protofibrils, Lenvima is a multi-kinase inhibitor involved in tumor angiogenesis, and Dayvigo is a novel small molecule compound. Sales extend to Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia and the Global South.

Headquarters
Tokyo, Japan
Employees
10,543
Founded
1941
Chief executive
Haruo Naito
Eisai and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Eisai4523$9.14B6.7%33.3+11.79%
Kyowa Kirin4151$8.46B21.8%16.6+9.73%
CiplaCIPLA$11.93B13.0%38.8−2.63%
Zhejiang NHU002001$12.3B33.8%10.9−21.99%
Zydus LifesciencesZYDUSLIFE$12.59B17.2%28.4+17.82%
Laurus LabsLAURUSLABS$13.9B24.1%97.8+67.72%

Same industry or related industries, similar size. Compare Eisai with its competitors · Full profile